英發(fā)現(xiàn)FPG是預(yù)測(cè)高血壓患者新發(fā)糖尿病的最佳指標(biāo)
 
根據(jù)一項(xiàng)大型臨床試驗(yàn)亞組資料分析顯示，空腹血漿葡萄糖(FPG)是高血壓患者是預(yù)測(cè)高血壓患者新發(fā)糖尿病最好的預(yù)測(cè)因子。

對(duì)盎格魯-斯堪的納維亞人心臟預(yù)后臨床試驗(yàn)-降低血壓分部(ASCOT-BPLA)期間患上糖尿病患者的資料分析，研究人員制定出了危險(xiǎn)評(píng)分，區(qū)分在抗高血壓治療期間新發(fā)糖尿病(NOD)危險(xiǎn)性最高的患者。在2006年9月西班牙巴塞羅那舉行的2006世界心臟病學(xué)大會(huì)上，由來自英國(guó)倫敦帝國(guó)大學(xué)的Ajay K. Gupta醫(yī)學(xué)博士進(jìn)行了報(bào)道。

Glucose Best Predicts Diabetes in Hypertension Patients
 
Fasting plasma glucose (FPG) may be the best predictor of risk of new-onset diabetes in hypertension patients, according to a subgroup analysis of data from a major trial.

Analysis of patients who developed diabetes during the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) has allowed investigators to create a risk score that appears to discriminate those at highest risk for development of new-onset diabetes (NOD) during antihypertensive therapy. The analysis was presented in September 2006 in Barcelona (Spain) at the World Congress of Cardiology 2006 by Ajay K. Gupta, M.D., from Imperial College London (UK).